Background
Comprehensive review of triple-negative breast cancer (TNBC) brain metastases; synthesis of SRS, hippocampal-avoidance WBRT, and systemic therapy integration; N not applicable (literature review).
Interventions and follow up
Arm A: Stereotactic radiosurgery (SRS) ± hippocampal avoidance
Arm B: Whole-brain radiotherapy (WBRT); transition toward HA-WBRT preferred to minimize cognition decline
Primary endpoint: Overall survival, progression-free survival, cognitive preservation, CNS control
mFollow up: 2–5 years (varies by series)
Arm B: Whole-brain radiotherapy (WBRT); transition toward HA-WBRT preferred to minimize cognition decline
Primary endpoint: Overall survival, progression-free survival, cognitive preservation, CNS control
mFollow up: 2–5 years (varies by series)
Results
Key findings from literature: SRS favored over WBRT for 1–4 lesions; HA-WBRT emerging standard for 5–20 metastases. Intracranial control 80–90% at 6 months with combined SRS/HA-WBRT. CNS-penetrant systemic agents (HER2 antibodies, tucatinib) improve extracranial control and may reduce CNS recurrence.
Adverse events
Main adverse events: Radiation necrosis 5–10% (SRS); cognitive decline reduced with HA-WBRT vs conventional WBRT; systemic therapy toxicity (grade ≥3) 20–30% across studies.
Conclusions
TNBC-BM management evolving toward selective local approaches (SRS, HA-WBRT) with CNS-penetrant systemic therapy; multimodal strategy superior to monotherapy.
Key Limitations
Key Limitations: Retrospective majority of evidence; limited prospective head-to-head RCTs comparing SRS vs HA-WBRT in TNBC specifically; heterogeneous systemic regimens across series; follow-up constraints in some cohorts.
Clinical Context
Shift away from WBRT monotherapy toward preservation-focused local + systemic integration. HER2-targeting (pertuzumab, trastuzumab, tucatinib) and PD-L1 inhibitors (atezolizumab + chemotherapy) increasingly incorporated; ongoing ASCO/NCCN guideline refinement expected.
References
References: Yang et al, Cancers 2026